Built by someone who lived the problem.

Twenty years of healthcare leadership. One clear conviction.

Ryan Bell has spent more than two decades as a healthcare executive, operating across the full continuum of hospital administration, medical device commercialization, and health system financial strategy. Over the course of his career, he has held P&L responsibility for portfolios representing hundreds of millions in revenue - and has sat on both sides of the table when capital decisions are made.

That vantage point exposed a pattern that repeated itself too often: promising medical technologies failing - not in clinical trials, but in the pitch, at the Value Analysis Committee, and ultimately in the market. The root cause was rarely the device itself. It was the absence of a shared financial lens that could translate clinical value into the economic language that CFOs, supply chain leaders, and VAC members need to approve a purchase.

Device manufacturers would launch products without understanding where their technology fit within a hospital's DRG economics, reimbursement corridors, or existing cost structure. Hospitals would evaluate new technology against incomplete data - often relying on vendor-supplied projections that couldn't survive a rigorous financial review. The result: delayed decisions, missed adoption windows, and billions left on the table across the industry every year.

The thesis behind Alpha VZN

Alpha VZN was created from the conviction that predictive modeling, powered by actual price transparency intelligence and real-world claims data, could fundamentally change how healthcare financial decisions are made. By giving hospitals and health systems a clinical-economic operating picture - one grounded in facility-level utilization data, payer mix dynamics, and benchmarked pricing - leadership teams can evaluate technology and service line investments with the same rigor they apply to any other capital decision.

For medical device and MedTech companies, that same intelligence becomes a go-to-market advantage. Alpha VZN enables commercial teams to identify where a device fits within a target facility's financial ecosystem, model the economic case before first contact, and even pressure-test pricing strategy prior to launch - transforming a sales conversation from a clinical pitch into a buyer-ready financial narrative.

And for hospital contracts and managed care teams, Alpha VZN delivers something the industry has lacked: leverage grounded in data at the payor negotiation table. By surfacing facility-level reimbursement benchmarks, regional rate comparisons, and case mix acuity intelligence, contracting teams can walk into negotiations with commercial insurers and Medicare Advantage plans armed with the evidence to justify higher rates, push back on unfavorable terms, and ensure that what the hospital is paid reflects the true complexity and cost of the care it delivers.